KRT-232 and TKI Study in Chronic Myeloid Leukemia

Official Title

An Open-Label, Multicentre, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With a Tyrosine Kinase Inhibitor (TKI) in Patients With Relapsed or Refractory Ph+ Chronic Myeloid Leukemia (CML)


This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia (CML) who have relapsed or are refractory or intolerant to a Tyrosine Kinase Inhibitor (TKI).

This study is a global, open label Phase 1b/2 to determine the efficacy and safety of KRT-232 in patients with chronic phase CML (CML-CP) and accelerated phase (CML-AP) who have failed TKI treatments.

Trial Description

Primary Outcome:

  • Part 1: Maximum tolerated dose (MTD)/maximum administered dose (MAD) of KRT-232
  • Part 2, Arm A and B: Major molecular response (MMR) rate
  • Part 2, Arm C: Major hematological response (MaHR) rate
Secondary Outcome:
  • CCyR rate
  • MCyR rate
  • Duration of response
  • Rate of complete hematologic response (CHR)
  • Progression-free survival (PFS) in each Arm
  • Overall survival (OS) in each Arm

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society